Acknowledging the Clinical Heterogeneity of Lupus Erythematosus

Chapter
First Online:

Abstract

The diagnosis “Lupus erythematosus” (LE) encompasses a heterogeneous group of mostly photosensitive autoimmune diseases. LE patients may present with a broad range of clinical signs, ranging from localized skin lesions to severe systemic disease with affection of internal organ systems. This chapter provides an overview of the classification of LE, reviews the current knowledge of pathophysiology, genomics, and transcriptomics, and details different pathophysiology-based therapeutic strategies within the specific LE-subsets.

Keywords

Cutaneous Lupus Erythematosus Diaminodiphenyl Sulfone Subcorneal Pustular Dermatosis Interface Dermatitis Systemic Lupus International Collaborate Clinic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014;48–49:14–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Parodi A, Rebora A. ARA and EADV criteria for classification of systemic lupus erythematosus in patients with cutaneous lupus erythematosus. Dermatology. 1997;194(3):217–20.CrossRefPubMedGoogle Scholar
  4. 4.
    Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Baltaci M, Fritsch P. Histologic features of cutaneous lupus erythematosus. Autoimmun Rev. 2009;8(6):467–73.CrossRefPubMedGoogle Scholar
  6. 6.
    Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev. 2005;4(5):253–63.CrossRefPubMedGoogle Scholar
  7. 7.
    Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol. 1979;115(12):1409–15.CrossRefPubMedGoogle Scholar
  8. 8.
    Schmitt V, Meuth AM, Amler S, Kuehn E, Haust M, Messer G, et al. Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus. Br J Dermatol. 2010;162(1):64–73.CrossRefPubMedGoogle Scholar
  9. 9.
    Tomasini D, Mentzel T, Hantschke M, Cerri A, Paredes B, Rutten A, et al. Plasmacytoid dendritic cells: an overview of their presence and distribution in different inflammatory skin diseases, with special emphasis on Jessner’s lymphocytic infiltrate of the skin and cutaneous lupus erythematosus. J Cutan Pathol. 2010;37(11):1132–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Wenzel J, Tuting T. Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. Exp Dermatol. 2007;16(5):454–63.CrossRefPubMedGoogle Scholar
  11. 11.
    Arai S, Katsuoka K. Clinical entity of Lupus erythematosus panniculitis/lupus erythematosus profundus. Autoimmun Rev. 2009;8(6):449–52.CrossRefPubMedGoogle Scholar
  12. 12.
    Miyashita A, Fukushima S, Makino T, Yoshino Y, Yamashita J, Honda N, et al. Proportion of lymphocytic inflammation with CD123 positive cells in lupus erythematous profundus predict a clinical response to treatment. Acta Derm Venereol. 2014;94:563–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Millard LG, Rowell NR. Chilblain lupus erythematosus (Hutchinson). A clinical and laboratory study of 17 patients. Br J Dermatol. 1978;98(5):497–506.CrossRefPubMedGoogle Scholar
  14. 14.
    Gunther C, Hillebrand M, Brunk J, Lee-Kirsch MA. Systemic involvement in TREX1-associated familial chilblain lupus. J Am Acad Dermatol. 2013;69(4):e179–81.CrossRefPubMedGoogle Scholar
  15. 15.
    Wenzel J, Bauer R, Bieber T, Bohm I. Autoantibodies in patients with Lupus erythematosus: spectrum and frequencies. Dermatology. 2000;201(3):282–3.CrossRefPubMedGoogle Scholar
  16. 16.
    Wenzel J, Brahler S, Bauer R, Bieber T, Tuting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005;153(1):157–62.CrossRefPubMedGoogle Scholar
  17. 17.
    Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med. 1990;227(3):207–10.CrossRefPubMedGoogle Scholar
  18. 18.
    Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610–5.CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Baechler EC, Batliwalla FM, Reed AM, Peterson EJ, Gaffney PM, Moser KL, et al. Gene expression profiling in human autoimmunity. Immunol Rev. 2006;210:120–37.CrossRefPubMedGoogle Scholar
  20. 20.
    Dall’era MC, Cardarelli PM, Preston BT, Witte A, Davis Jr JC. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis. 2005;64(12):1692–7.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Freutel S, Gaffal E, Zahn S, Bieber T, Tuting T, Wenzel J. Enhanced CCR5+/CCR3+ T helper cell ratio in patients with active cutaneous lupus erythematosus. Lupus. 2011;20(12):1300–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Wenzel J, Worenkamper E, Freutel S, Henze S, Haller O, Bieber T, et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol. 2005;205(4):435–42.CrossRefPubMedGoogle Scholar
  23. 23.
    Arrue I, Saiz A, Ortiz-Romero PL, Rodriguez-Peralto JL. Lupus-like reaction to interferon at the injection site: report of five cases. J Cutan Pathol. 2007;34 Suppl 1:18–21.CrossRefPubMedGoogle Scholar
  24. 24.
    Liu Z, Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med. 2012;18(6):871–82.CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Eloranta ML, Lovgren T, Finke D, Mathsson L, Ronnelid J, Kastner B, et al. Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 2009;60(8):2418–27.CrossRefPubMedGoogle Scholar
  26. 26.
    Arriens C, Mohan C. Systemic lupus erythematosus diagnostics in the ‘omics’ era. Int J Clin Rheumatol. 2013;8(6):671–87.CrossRefGoogle Scholar
  27. 27.
    Gunther C, Meurer M, Stein A, Viehweg A, Lee-Kirsch MA. Familial chilblain lupus–a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1. Dermatology. 2009;219(2):162–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA, et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet. 2007;39(9):1065–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Lee HS, Bae SC. What can we learn from genetic studies of systemic lupus erythematosus? Implications of genetic heterogeneity among populations in SLE. Lupus. 2010;19(12):1452–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Dey-Rao R, Smith JR, Chow S, Sinha AA. Differential gene expression analysis in CCLE lesions provides new insights regarding the genetics basis of skin vs. systemic disease. Genomics. 2014;104:144–55.CrossRefPubMedGoogle Scholar
  31. 31.
    Hornung T, Ko A, Tuting T, Bieber T, Wenzel J. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clin Exp Dermatol. 2012;37(2):139–42.CrossRefPubMedGoogle Scholar
  32. 32.
    Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45(3):420–34.CrossRefPubMedGoogle Scholar
  33. 33.
    Kast RE, Scheuerle A, Wirtz CR, Karpel-Massler G, Halatsch ME. The rationale of targeting neutrophils with dapsone during glioblastoma treatment. Anticancer Agents Med Chem. 2011;11(8):756–61.CrossRefPubMedGoogle Scholar
  34. 34.
    Piette EW, Werth VP. Dapsone in the management of autoimmune bullous diseases. Immunol Allergy Clin North Am. 2012;32(2):317–22, vii.CrossRefPubMedCentralPubMedGoogle Scholar
  35. 35.
    Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186(8):4794–804.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of DermatologyUniversity Clinic BonnBonnGermany

Personalised recommendations